Article info
PDFEditorial commentary
Using clinically stable disease (NEDA 2) as a proxy for disease impact and employment in MS paints an incomplete picture
- Correspondence to Sharon Roman, Vancouver, British Columbia, Canada; slhroman{at}gmail.com
Citation
Using clinically stable disease (NEDA 2) as a proxy for disease impact and employment in MS paints an incomplete picture
Publication history
- Received September 9, 2019
- Accepted September 14, 2019
- First published November 14, 2019.
Online issue publication
March 17, 2020
Article Versions
- Previous version (17 March 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.